PCP Prophylaxis in Nephrotic Syndrome
Primary Indication: PCP Prophylaxis
- The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend prophylactic trimethoprim-sulfamethoxazole for patients with nephrotic syndrome who are receiving high-dose prednisone or other immunosuppressive agents, including rituximab and cyclophosphamide, to prevent Pneumocystis jirovecii pneumonia (PCP) 1, 2
- The combination of immunosuppressive medications, nephrotic syndrome, uremia, and malnutrition substantially elevates the infection risk in these patients 1
Mechanism of Increased Infection Risk
- Nephrotic syndrome causes a loss of immunoglobulins through urinary protein loss, leading to disease-related immunosuppression 1
- Treatment with corticosteroids, rituximab, and cyclophosphamide profoundly suppresses cellular and humoral immunity, further increasing the infection risk 1, 2
Additional Considerations Before Starting Immunosuppression
- The KDIGO guidelines emphasize the need for a comprehensive infection screening protocol before initiating immunosuppressive therapy in nephrotic syndrome patients, including screening for tuberculosis, hepatitis B and C, HIV, and syphilis 1, 2
- Patients from endemic tropical regions should be evaluated for Strongyloides, particularly those with eosinophilia and elevated IgE 1, 2
- Vaccinations, including pneumococcal, influenza, and herpes zoster (Shingrix), should be updated before starting immunosuppression 1, 3